Matthew Lombardo
Merck & Co., Inc., Rahway, NJ, USA (United States)(US)
Publications by Year
Research Areas
Diabetes Treatment and Management, Neuropeptides and Animal Physiology, Receptor Mechanisms and Signaling, Synthesis and biological activity, Melanoma and MAPK Pathways
Most-Cited Works
- → Design and Synthesis of Prolylcarboxypeptidase (PrCP) Inhibitors To Validate PrCP As A Potential Target for Obesity(2010)51 cited
- → Design, Synthesis, and Evaluation of Novel and Selective G-protein Coupled Receptor 120 (GPR120) Spirocyclic Agonists(2016)32 cited
- → Discovery of benzofuran propanoic acid GPR120 agonists: From uHTS hit to mechanism-based pharmacodynamic effects(2016)24 cited
- → Novel 1-(2-aminopyrazin-3-yl)methyl-2-thioureas as potent inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK-2)(2009)21 cited
- → Discovery and development of benzo-[1,2,4]-triazolo-[1,4]-oxazepine GPR142 agonists for the treatment of diabetes(2016)15 cited
- → Discovery of a new class of potent prolylcarboxypeptidase inhibitors derived from alanine(2011)11 cited
- → Design, synthesis, and biological evaluation of aminopyrazine derivatives as inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK-2)(2015)11 cited
- → Structure Guided Discovery of Novel Pan Metallo-β-Lactamase Inhibitors with Improved Gram-Negative Bacterial Cell Penetration(2024)6 cited
- → The Discovery of a Novel Anticoagulant Mechanism: Factor XI Activation Inhibitors(2025)
- → Corrigendum to “Discovery of benzofuran propanoic acid GPR120 agonists: From uHTS hit to mechanism-based pharmacodynamic effects” [Bioorg. Med. Chem. Lett. 26 (2016) 5724–5728](2017)